MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2021013733

Медицинская библиотека · Blood · 2022

Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.

Qi Yuekun, Zhao Mingfeng, Hu Yongxian, Wang Ying, Li Ping, Cao Jiang, Shi Ming, Tan Jiaqi, Zhang Meng, Xiao Xia, Xia Jieyun, Ma Sha, Qiao Jianlin, Yan Zhiling, Li Hujun, Pan Bin, Sang Wei, Li Depeng, Li Zhenyu, Zhou Jianfeng, Huang He, Liang Aibin, Zheng Junnian, Xu Kailin

Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system leukemia (CNSL) because of concerns regarding poor response and treatment-related neurotoxicity. Our study included 48 patients with relapsed/refractory B-ALL with CNSL to evaluate the efficacy and safety of CD19-specific CAR T cell-based therapy. The infusion resulted in an overall response rate of 87.5% (95% confidence interval [CI], 75.3-94.1) in bone marrow (BM) disease and remission rate of 85.4% (95% CI, 72.8-92.8) in CNSL. With a median follow-up of 11.5 months (range, 1.3-33.3), the median event-free survival was 8.7 months (95% CI, 3.7-18.8), and the median overall survival was 16.0 months (95% CI, 13.5-20.1). The cumulative incidences of relapse in BM and CNS diseases were 31.1% and 11.3%, respectively, at 12 months (P = .040). The treatment was generally well tolerated, with 9 patients (18.8%) experiencing grade ≥3 cytokine release syndrome. Grade 3 to 4 neurotoxic events, which developed in 11 patients (22.9%), were associated with a higher preinfusion disease burden in CNS and were effectively controlled under intensive management. Our results suggest that CD19-specific CAR T cell-based therapy can induce similar high response rates in both BM and CNS diseases. The duration of remission in CNSL was longer than that in BM disease. CD19 CAR T-cell therapy may provide a potential treatment option for previously excluded patients with CNSL, with manageable neurotoxicity. The clinical trials were registered at www.clinicaltrials.gov as #NCT02782351 and www.chictr.org.cn as #ChiCTR-OPN-16008526.

Для цитирования: Qi Yuekun, Zhao Mingfeng, Hu Yongxian, Wang Ying, Li Ping, Cao Jiang, Shi Ming, Tan Jiaqi, Zhang Meng, Xiao Xia, Xia Jieyun, Ma Sha, Qiao Jianlin, Yan Zhiling, Li Hujun, Pan Bin, Sang Wei, Li Depeng, Li Zhenyu, Zhou Jianfeng, Huang He, Liang Aibin, Zheng Junnian, Xu Kailin. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.. Blood. 2022. DOI: 10.1182/blood.2021013733.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.